Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor
| Class:Id | LiteratureReference:9713886 |
|---|---|
| _displayName | Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor |
| _timestamp | 2021-02-02 01:30:16 |
| author | [Person:9713887] Lee, Jiyun [Person:9713888] Sun, Jong-Mu [Person:8853022] Lee, Se-Hoon [Person:9713884] Ahn, Jin Seok [Person:9713883] Park, Keunchil [Person:9713882] Choi, Yoon La [Person:9713885] Ahn, Myung-Ju |
| created | [InstanceEdit:9713889] Rothfels, Karen, 2021-02-02 |
| journal | Clin Lung Cancer |
| pages | 215-221 |
| pubMedIdentifier | 30683630 |
| title | Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor |
| volume | 20 |
| year | 2019 |
| (literatureReference) | [DefinedSet:9700553] ceritinib-resistant ALK mutants [plasma membrane] [Homo sapiens] [FailedReaction:9700658] ceritinib-resistant ALK mutants don't bind ceritinib [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor (9713886)
